H.C. Wainwright 23rd Annual Global Investment Conference
We are leveraging our core competencies and decade of experience in antiviral therapeutics to combat the global COVID-19 health crisis. Our COVID-19 program consists of work performed by our contract research organization partners around the world and in our own laboratory. Given the growing global need for a treatment, we are advancing preclinical development of antiviral therapeutics targeting SARS-CoV-2 as quickly and efficiently as possible, while advancing the discovery and development of antiviral compounds for other high-value indications.
Seoul, South Korea
New York, NY
Be the first to receive breaking newsSign Up